BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products

PHOENIX, July 31, 2025 ~ Phoenix-based medical manufacturer, BioLab Holdings, Inc., has announced the launch of its most comprehensive clinical trial to date. The trial, titled "A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP)," aims to evaluate the effectiveness of four human placental membrane (HPM) products in combination with standard of care (SOC) for treating nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).

The trial will enroll 650 participants across up to 30 clinical sites nationwide. According to Dr. Marshall Medley, chief medical officer at BioLab, this study marks a significant milestone in their commitment to advancing wound care through rigorous clinical research. He stated that by evaluating their full suite of amnion-based products in a real-world setting, they hope to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.

More on Rezul News

• Costa Oil Partners with Rick Ware Racing for NASCAR Cup Series Debut at Iowa Speedway
• Illinois Discount Realty Announces Launch of Their 1% Full Service Real Estate Brokerage
• DARA Abrams NYC Stories Art Experience at One Art Space
• Buildout Unveils Rethink+: Revolutionizing Commercial Real Estate Prospecting with Seamless CRM Integration
• purelyIV Launches Niagen® IV Therapy – A Breakthrough in NAD+ Cellular Wellness

Participants will be randomly assigned to receive one of four BioLab products – Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4) – in addition to SOC or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms.

The study is designed to capture real-world clinical outcomes and contribute to the growing body of evidence supporting the use of placental-derived allografts in chronic wound management. For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, interested parties can visit their website at biolabholdings.net.

---

Show All News | Report Violation